{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:16:58Z","timestamp":1783563418044,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K18684"],"award-info":[{"award-number":["19K18684"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K27431"],"award-info":[{"award-number":["23K27431"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K08879"],"award-info":[{"award-number":["23K08879"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K21665"],"award-info":[{"award-number":["20K21665"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While immune checkpoint inhibitors (ICIs) have failed to improve outcomes in unselected ovarian cancer populations, objective responses are observed in a minority of ovarian clear cell carcinoma (OCCC) cases, implying biological heterogeneity and a yet-undefined immunologically responsive subset within this histotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed immunohistochemical profiling of tumor-infiltrating immune cells and analyzed transcriptomic data from human OCCC cohorts. Functional studies were conducted using an immunocompetent syngeneic OCCC mouse model to assess the effects of IL-17 on tumor cell inflammatory signaling, immune microenvironment remodeling, and responsiveness to immune checkpoint blockade, including single-cell RNA sequencing of tumor-infiltrating T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      OCCC exhibited an immune-sparse tumor microenvironment with relative enrichment of CD4\u207a T cells.\n                      <jats:italic>RORC<\/jats:italic>\n                      expression was elevated in OCCC but showed intertumoral heterogeneity. In the transcriptome data (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009180), an\n                      <jats:italic>IL17A<\/jats:italic>\n                      <jats:sup>high<\/jats:sup>\n                      subset (5%), enriched within the\n                      <jats:italic>RORC<\/jats:italic>\n                      <jats:sup>high<\/jats:sup>\n                      fraction, exhibited a T cell\u2013inflamed gene expression profile independent of microsatellite instability and tumor mutational burden, yet was not associated with survival. Mechanistically, IL-17 directly activated NF-\u03baB\u2013dependent inflammatory programs in OCCC tumor cells, inducing cytokines and chemokines involved in T-cell recruitment and activation. In the syngeneic model, IL-17 exposure increased intratumoral CD4\u207a and CD8\u207a T-cell infiltration and activation. Single-cell profiling further revealed expansion of Th17\/Tfh-like CD4\u207a T cells and cytotoxic, non-terminally exhausted CD8\u207a T cells. Consistent with these changes, anti\u2013PD-L1 therapy improved survival in Th17-biased partial chimera mice.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IL-17\u2013responsive, tumor cell\u2013intrinsic inflammatory programming remodels the tumor immune microenvironment toward an immunotherapy-permissive state. These findings establish IL-17\u2013responsive tumor cell inflammatory programming as a mechanistic axis shaping immune checkpoint sensitivity and provide a rationale for biomarker-guided immunotherapy strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-026-02726-2","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:36:58Z","timestamp":1782790618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL-17\u2013driven tumor cell\u2013intrinsic inflammatory programming creates an immunotherapy-permissive microenvironment"],"prefix":"10.1186","volume":"25","author":[{"given":"Kosuke","family":"Murakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiki","family":"Takamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiho","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Hakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Tsuji-Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kakimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriomi","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"2726_CR1","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10147-024-02473-8","volume":"29","author":"H Nakai","year":"2024","unstructured":"Nakai H, Higashi T, Kakuwa T, Matsumura N. Trends in gynecologic cancer in Japan: incidence from 1980 to 2019 and mortality from 1981 to 2021. Int J Clin Oncol. 2024;29:363\u201371.","journal-title":"Int J Clin Oncol"},{"key":"2726_CR2","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1097\/IGC.0000000000000289","volume":"24","author":"A Okamoto","year":"2014","unstructured":"Okamoto A, Glasspool RM, Mabuchi S, Matsumura N, Nomura H, Itamochi H, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2014;24:S20\u20135.","journal-title":"Int J Gynecol Cancer"},{"key":"2726_CR3","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.3802\/jgo.2016.27.e31","volume":"27","author":"S Mabuchi","year":"2016","unstructured":"Mabuchi S, Sugiyama T, Kimura T. Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives. J Gynecol Oncol. 2016;27:e31.","journal-title":"J Gynecol Oncol"},{"key":"2726_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"2726_CR5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.ajpath.2015.12.029","volume":"186","author":"R Murakami","year":"2016","unstructured":"Murakami R, Matsumura N, Mandai M, Yoshihara K, Tanabe H, Nakai H, et al. Establishment of a novel histopathological classification of high-grade serous ovarian carcinoma correlated with prognostically distinct gene expression subtypes. Am J Pathol. 2016;186:1103\u201313.","journal-title":"Am J Pathol"},{"key":"2726_CR6","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.3802\/jgo.2023.34.e47","volume":"34","author":"C Miyagawa","year":"2023","unstructured":"Miyagawa C, Nakai H, Otani T, Murakami R, Takamura S, Takaya H, et al. Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging. J Gynecol Oncol. 2023;34:e47.","journal-title":"J Gynecol Oncol"},{"key":"2726_CR7","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, et al. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J Clin Oncol. 2021;39:1842\u201355.","journal-title":"J Clin Oncol"},{"key":"2726_CR8","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021;22:1034\u201346.","journal-title":"Lancet Oncol"},{"key":"2726_CR9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","volume":"22","author":"BJ Monk","year":"2021","unstructured":"Monk BJ, Colombo N, Oza AM, Fujiwara K, Birrer MJ, Randall L, et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:1275\u201389.","journal-title":"Lancet Oncol"},{"key":"2726_CR10","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1200\/JCO.21.00334","volume":"39","author":"J Hamanishi","year":"2021","unstructured":"Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J Clin Oncol. 2021;39:3671\u201381.","journal-title":"J Clin Oncol"},{"key":"2726_CR11","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1200\/JCO.23.00529","volume":"41","author":"JE Kurtz","year":"2023","unstructured":"Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, et al. Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 Trial. J Clin Oncol. 2023;41:4768\u201378.","journal-title":"J Clin Oncol"},{"key":"2726_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41698-024-00640-8","volume":"8","author":"C Mateiou","year":"2024","unstructured":"Mateiou C, Lokhande L, Diep LH, Knulst M, Carlsson E, Ek S, et al. Spatial tumor immune microenvironment phenotypes in ovarian cancer. NPJ Precis Oncol. 2024;8:148.","journal-title":"NPJ Precis Oncol"},{"key":"2726_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jamaoncol.2024.6797","volume":"11","author":"R Kristeleit","year":"2025","unstructured":"Kristeleit R, Devlin MJ, Clamp A, Gourley C, Roux R, Hall M, et al. Pembrolizumab in patients with advanced clear cell gynecological cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol. 2025;11:377\u201385.","journal-title":"JAMA Oncol"},{"key":"2726_CR14","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33:4015\u201322.","journal-title":"J Clin Oncol"},{"key":"2726_CR15","doi-asserted-by":"publisher","first-page":"11427","DOI":"10.1038\/s41598-021-91012-w","volume":"11","author":"R Murakami","year":"2021","unstructured":"Murakami R, Hamanishi J, Brown JB, Abiko K, Yamanoi K, Taki M, et al. Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. Sci Rep. 2021;11:11427.","journal-title":"Sci Rep"},{"key":"2726_CR16","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1038\/onc.2009.470","volume":"29","author":"K Yamaguchi","year":"2010","unstructured":"Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Baba T, et al. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene. 2010;29:1741\u201352.","journal-title":"Oncogene"},{"key":"2726_CR17","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1158\/1078-0432.CCR-10-3314","volume":"17","author":"MS Anglesio","year":"2011","unstructured":"Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011;17:2538\u201348.","journal-title":"Clin Cancer Res"},{"key":"2726_CR18","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/mc.22325","volume":"55","author":"N Yanaihara","year":"2016","unstructured":"Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, et al. Antitumor effects of interleukin-6 (IL-6)\/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Mol Carcinog. 2016;55:832\u201341.","journal-title":"Mol Carcinog"},{"key":"2726_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00262-026-04324-z","volume":"75","author":"K Hamada","year":"2026","unstructured":"Hamada K, Hamanishi J, Ueda A, Takamatsu S, Yoshihara K, Nagasawa T, et al. AI-based quantification of tumor-infiltrating lymphocytes with integrative transcriptomics in ovarian clear cell carcinoma: JGOG3025-TR1\/A1 study. Cancer Immunol Immunother. 2026;75:81.","journal-title":"Cancer Immunol Immunother"},{"key":"2726_CR20","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ng0506-500","volume":"38","author":"M Reich","year":"2006","unstructured":"Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. Genepattern 2.0. Nat Genet. 2006;38:500\u20131.","journal-title":"Nat Genet"},{"key":"2726_CR21","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u201340.","journal-title":"J Clin Invest"},{"key":"2726_CR22","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362:eaar3593.","journal-title":"Science"},{"key":"2726_CR23","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/s41416-024-02837-x","volume":"131","author":"S Takamatsu","year":"2024","unstructured":"Takamatsu S, Hillman RT, Yoshihara K, Baba T, Shimada M, Yoshida H, et al. Molecular classification of ovarian high-grade serous\/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study. Br J Cancer. 2024;131:1340\u20139.","journal-title":"Br J Cancer"},{"key":"2726_CR24","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1038\/ncomms7118","volume":"6","author":"RL Chandler","year":"2015","unstructured":"Chandler RL, Damrauer JS, Raab JR, Schisler JC, Wilkerson MD, Didion JP, et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat Commun. 2015;6:6118.","journal-title":"Nat Commun"},{"key":"2726_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nm0795-649","volume":"1","author":"LD Falo Jr","year":"1995","unstructured":"Falo LD Jr, Kovacsovics-Bankowski M, Thompson K, Rock KL. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med. 1995;1:649\u201353.","journal-title":"Nat Med"},{"key":"2726_CR26","doi-asserted-by":"publisher","first-page":"e52330","DOI":"10.7554\/eLife.52330","volume":"9","author":"A Kumar","year":"2020","unstructured":"Kumar A, Chamoto K, Chowdhury PS, Honjo T. Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy. Elife. 2020;9:e52330.","journal-title":"Elife"},{"key":"2726_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14:417\u20139.","journal-title":"Nat Methods"},{"key":"2726_CR28","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12859-018-2486-6","volume":"19","author":"SX Ge","year":"2018","unstructured":"Ge SX, Son EW, Yao R. iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinformatics. 2018;19:534.","journal-title":"BMC Bioinformatics"},{"key":"2726_CR29","doi-asserted-by":"publisher","first-page":"9175","DOI":"10.1038\/s41467-025-64107-5","volume":"16","author":"M Takahashi","year":"2025","unstructured":"Takahashi M, Tsunoda M, Aoki H, Kurosu M, Ogiwara H, Shichino S, et al. A pan-immunotherapy signature to predict intratumoral CD8+ T cell expansions. Nat Commun. 2025;16:9175.","journal-title":"Nat Commun"},{"key":"2726_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357\u20139.","journal-title":"Nat Methods"},{"key":"2726_CR31","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573\u201387.","journal-title":"Cell"},{"key":"2726_CR32","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1002\/eji.201142250","volume":"42","author":"K Yoh","year":"2012","unstructured":"Yoh K, Morito N, Ojima M, Shibuya K, Yamashita Y, Morishima Y, et al. Overexpression of ROR\u03b3t under control of the CD2 promoter induces polyclonal plasmacytosis and autoantibody production in transgenic mice. Eur J Immunol. 2012;42:1999\u20132009.","journal-title":"Eur J Immunol"},{"key":"2726_CR33","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3892\/ijo.2012.1533","volume":"41","author":"N Yanaihara","year":"2012","unstructured":"Yanaihara N, Anglesio MS, Ochiai K, Hirata Y, Saito M, Nagata C, et al. Cytokine gene expression signature in ovarian clear cell carcinoma. Int J Oncol. 2012;41:1094\u2013100.","journal-title":"Int J Oncol"},{"key":"2726_CR34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37:318\u201327.","journal-title":"J Clin Oncol"},{"key":"2726_CR35","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1016\/j.ajpath.2017.06.012","volume":"187","author":"R Murakami","year":"2017","unstructured":"Murakami R, Matsumura N, Brown JB, Higasa K, Tsutsumi T, Kamada M, et al. Exome sequencing landscape analysis in ovarian clear cell carcinoma shed light on key chromosomal regions and mutation gene networks. Am J Pathol. 2017;187:2246\u201358.","journal-title":"Am J Pathol"},{"key":"2726_CR36","doi-asserted-by":"publisher","first-page":"e21816","DOI":"10.1371\/journal.pone.0021816","volume":"6","author":"J Li","year":"2011","unstructured":"Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, et al. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS ONE. 2011;6:e21816.","journal-title":"PLoS ONE"},{"key":"2726_CR37","doi-asserted-by":"publisher","first-page":"e96678","DOI":"10.1371\/journal.pone.0096678","volume":"9","author":"Y Wang","year":"2014","unstructured":"Wang Y, Wu H, Wu X, Bian Z, Gao Q. Interleukin 17A promotes gastric cancer invasiveness via NF-\u03baB mediated matrix metalloproteinases 2 and 9 expression. PLoS ONE. 2014;9:e96678.","journal-title":"PLoS ONE"},{"key":"2726_CR38","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.imlet.2017.02.006","volume":"184","author":"X Wang","year":"2017","unstructured":"Wang X, Yang L, Huang F, Zhang Q, Liu S, Ma L, et al. Inflammatory cytokines IL-17 and TNF-\u03b1 up-regulate PD-L1 expression in human prostate and colon cancer cells. Immunol Lett. 2017;184:7\u201314.","journal-title":"Immunol Lett"},{"key":"2726_CR39","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.canlet.2019.01.008","volume":"447","author":"B Wang","year":"2019","unstructured":"Wang B, Zhao CH, Sun G, Zhang ZW, Qian BM, Zhu YF, et al. IL-17 induces the proliferation and migration of glioma cells through the activation of PI3K\/Akt1\/NF-\u03baB-p65. Cancer Lett. 2019;447:93\u2013104.","journal-title":"Cancer Lett"},{"key":"2726_CR40","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature04753","volume":"441","author":"E Bettelli","year":"2006","unstructured":"Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235\u20138.","journal-title":"Nature"},{"key":"2726_CR41","doi-asserted-by":"publisher","first-page":"e20190297","DOI":"10.1084\/jem.20190297","volume":"217","author":"J Zhao","year":"2020","unstructured":"Zhao J, Chen X, Herjan T, Li X. The role of interleukin-17 in tumor development and progression. J Exp Med. 2020;217:e20190297.","journal-title":"J Exp Med"},{"key":"2726_CR42","doi-asserted-by":"publisher","first-page":"bgae079","DOI":"10.1093\/carcin\/bgae079","volume":"46","author":"E Begagic","year":"2025","unstructured":"Begagic E, Vranic S, Sominanda A. The role of interleukin 17 in cancer: a systematic review. Carcinogenesis. 2025;46:bgae079.","journal-title":"Carcinogenesis"},{"key":"2726_CR43","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1182\/blood-2009-03-208249","volume":"114","author":"I Kryczek","year":"2009","unstructured":"Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood. 2009;114:1141\u20139.","journal-title":"Blood"},{"key":"2726_CR44","doi-asserted-by":"publisher","first-page":"e007661","DOI":"10.1136\/jitc-2023-007661","volume":"11","author":"Y Luo","year":"2023","unstructured":"Luo Y, Shreeder B, Jenkins JW, Shi H, Lamichhane P, Zhou K, et al. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade. J Immunother Cancer. 2023;11:e007661.","journal-title":"J Immunother Cancer"},{"key":"2726_CR45","unstructured":"National Library of Medicine. ClinicalTrials.gov identifier NCT05920798: Phase 2 study of dendritic cell-based cancer vaccine. ClinicalTrials.gov. Accessed 25 Apr 2026."},{"key":"2726_CR46","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/s43018-023-00610-2","volume":"4","author":"R V\u00e1raljai","year":"2023","unstructured":"V\u00e1raljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, et al. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nat Cancer. 2023;4:1292\u2013308.","journal-title":"Nat Cancer"},{"key":"2726_CR47","doi-asserted-by":"crossref","unstructured":"Guglietta S, B\u00e4renwaldt A, Sonrel A, Orjuela S, Monaco G, Cahill T, et al. A Th17 signature correlates with response to dual CTLA-4 and PD-1 blockade in metastatic renal cell carcinoma. medRxiv. 2025;2025.09.29.25335360.","DOI":"10.1101\/2025.09.29.25335360"},{"key":"2726_CR48","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1007\/s10147-023-02397-9","volume":"28","author":"S Mishima","year":"2023","unstructured":"Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, et al. Japanese Society of Medical Oncology\/Japan Society of Clinical Oncology\/Japanese Society of Pediatric Hematology\/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition. Int J Clin Oncol. 2023;28:1237\u201358.","journal-title":"Int J Clin Oncol"},{"key":"2726_CR49","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s10147-023-02360-8","volume":"28","author":"S Mishima","year":"2023","unstructured":"Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, et al. Japanese Society of Medical Oncology\/Japan Society of Clinical Oncology\/Japanese Society of Pediatric Hematology\/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors. Int J Clin Oncol. 2023;28:941\u201355.","journal-title":"Int J Clin Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02726-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02726-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02726-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:02:20Z","timestamp":1783562540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02726-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2726"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02726-2","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted with the approval of the Institutional Review Board of Kindai University Faculty of Medicine (R03-084), and Kyoto University Graduate School and Faculty of Medicine (G531). Patients in this study were given an appropriate opportunity to refuse to participate in the study by opt-out on the website of Kindai University Faculty of Medicine (\n                      \n                      ), and Kyoto University Graduate School and Faculty of Medicine (\n                      \n                      ). This study was performed in accordance with the Declaration of Helsinki. Animal experiments were approved by Kindai University and the Animal Experiment Committee of Kindai University (KDMS-2021\u2013004, KAME-2024\u2013024).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Kosuke Murakami received a research grant from Eisai. Noriomi Matsumura received lecture fees from Chugai Pharmaceutical, AstraZeneca, and Takeda Pharmaceutical, as well as a research grant from AstraZeneca. Noriomi Matsumura is also an outside director of Takara Bio. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"168"}}